

Table of Content

Chapters	Title	Page No.
Chapter 1	Review of literature	1
1	Introduction	2
1.1	Sugar consumption global picture	2
1.2	Sugars metabolism	3
1.3	Metabolic effects of high intake of sugars	7
1.3.1	Dyslipidemia	7
1.3.2	Ectopic lipid deposition	8
1.3.3	Impaired insulin resistance and glucose homeostasis	9
1.3.4	Uric acid metabolism	9
1.3.5	High blood pressure	10
1.3.6	Sucrose forming advanced glycation products (AGEs)	12
1.3.7	The two hit theory	13
1.3.8	Fructose and gut microbe	15
1.3.9	Postnatal and prenatal fetal health consequences	16
1.3.10	Sucrose and cognitive impairment	18
1.3.11	Appetite signals	19
1.3.12	Mineral metabolism	20
1.4	Strategies employed for management of sugar induced metabolic syndrome	22
1.5	Human gut microbiota	23
1.6	Diversity, distribution and functionality of gut microflora	23
1.7	Probiotics	26
1.8	<i>Escherichia coli</i> as a probiotic	31
1.9	<i>Escherichia coli</i> Nissle 1917 (EcN)	31
1.10	Probiotics in remission of diseases	32
1.11	Possible advantage of target based probiotic development	35
1.11.1	Gut microbiota maturation and nutrition	48
1.11.2	EcN in the treatment of Inflammatory Bowel Diseases (IBD)	49

1.12	Oxidative stress and ROS	50
1.13	Antioxidants	53
1.14	Pyroloquinoline quinone (PQQ)	56
1.15	Factors influencing the colonization and survival of probiotics	58
1.16	<i>Vitreoscilla</i> Hemoglobin	60
1.17	Prebiotics	61
1.18	Inulosucrase (InuJ)	62
1.19	Short chain fatty acids (SCFAs)	64
Chapter 2	Evaluating the protective effect of probiotic <i>E. coli</i> 16 on 1, 2-dimethylhydrazine (DMH) induced oxidative stress	67
2	Introduction	68
2.1	Material and methods	71
2.1.1	Animals	71
2.1.2	Experimental design	71
2.1.3	Plasmids and constructs	72
2.1.4	Bacterial strains and culture conditions	73
2.1.5	PQQ extraction and quantification	73
2.1.6	Preparation of tissue homogenates	73
2.1.7	Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetate transaminase (SGOT) estimation	74
2.1.8	Estimation of norepinephrine (NE) and dopamine (DP)	74
2.1.9	Estimation of 5-Hydroxy tryptophan (5-HT)	74
2.1.10	Estimation of epinephrine	75
2.1.11	Superoxide dismutase	75
2.1.12	Catalase	75
2.1.13	Glutathione peroxidase activity assay	75
2.1.14	Histopathological changes	76
2.1.15	Statistical analysis	76
2.2	Results	77
2.2.1	Characterization and quantification of PQQ-producing probiotic <i>E. coli</i> CFR 16	77
2.2.2	Fecal PQQ quantification	77

2.2.3	Effect of probiotic <i>E. coli</i> CFR 16 on body weight and colon length	78
2.2.4	Serum SGOT and SGPT	78
2.2.5	Effect of probiotic <i>E. coli</i> CFR 16 on systemic antioxidant status	79
2.2.6	Effect of probiotic <i>E. coli</i> CFR 16 on liver and colon lipid peroxidation	80
2.2.7	Effect of probiotic <i>E. coli</i> CFR 16 on liver and colon antioxidant status	81
2.2.8	Colon histological analysis	82
2.2.9	Brain neurotransmitter status	85
2.3	Discussion	87
2.4	Conclusion	91
Chapter 3	Evaluating the effect of probiotic <i>E. coli</i> strains producing pyrroloquinoline quinone (PQQ) on fructose induced metabolic effect and antioxidant status in Charles Foster rats	92
3	Introduction	93
3.1	Material and methods	96
3.1.1	Animals, diet and experimental design	96
3.1.2	Plasmids, bacterial strains and culture conditions	96
3.1.3	PQQ extraction and quantification	97
3.1.4	Preparation of cell lysate and tissue homogenates	97
3.1.5	Biochemical assays	97
3.1.6	Colonic short chain fatty acid extraction and estimation	98
3.1.7	FAC and AOC mRNA expression and qRT-PCR in hepatic tissue	98
3.1.8	Statistical analysis	99
3.2	Results	100
3.2.1	Genomic integration of <i>gfp</i> and <i>vgb</i> in EcN	100
3.2.2	Colonization of EcN (<i>gfp</i>) and EcN:: <i>vgb-gfp</i> in rat intestine	101
3.2.3	Confirmation and characterization of EcN:: <i>vgb-gfp</i> (<i>pqq</i>)	101
3.2.4	Food intake, body weight gain, fasting glucose levels, serum	103

	insulin and uric acid levels	
3.2.5	Serum and hepatic lipid profile	103
3.2.6	Serum and hepatic LPO and antioxidant enzyme activities	104
3.2.7	Colonic short chain fatty acids (SCFAs)	105
3.2.8	mRNA expression of FAS and ACOx in hepatic tissue	105
3.3	Discussion	114
Chapter 4	Evaluating the effect of probiotic <i>E. coli</i> strains harboring plasmid and genomic integrants encoding pyrroloquinoline quinone (<i>pqq</i>) and inulosucrase (<i>inuJ</i>) gene cluster on sucrose fed Charles Foster rats.	118
4.	Introduction	119
4.1	Materials and method	123
4.1.1	Experimental design (Sucrose-plasmid based)	122
4.1.2	Experimental design (Sucrose-Genomic integrants)	123
4.2	Results (Sucrose plasmid based)	125
4.2.1	Sub-cloning, confirmation and functional characterization of EcN:: <i>vgb-gfp</i> (<i>pqq</i>) and EcN:: <i>vgb-gfp</i> (<i>pqq-inuJ</i>)	125
4.2.2	Effect of modified EcN on Body weight, food intake, glucose and serum insulin levels	127
4.2.3	Effect of modified EcN on serum and hepatic triglyceride levels	129
4.2.4	Effect of modified EcN on blood and liver antioxidant status	130
4.2.5	Effect of modified EcN on colonic short chain fatty acids (SCFAs)	130
4.2.6	Effect of modified EcN on mRNA expression profile of FAS, ACOX, PGC-1 α and Mit/Nuc DNA ratio	133
4.3	Result (Sucrose genomic integrants)	134
4.3.1	Genomic integration and characterization of EcN:: <i>vgb-gfp-pqq</i> and EcN:: <i>vgb-gfp-pqq-inuJ</i>	134
4.3.2	Effect of plasmid and genomic integrants of EcN on Body weight, fasting serum glucose and serum insulin levels	137
4.3.3	Effect of plasmid and genomic integrants of EcN on serum	138

	and liver lipid profile	
4.3.4	Effect of plasmid and genomic integrants of EcN on serum and liver antioxidant status	140
4.3.5	SCFA profile	142
4.3.6	Fecal gluconic acid concentration	142
4.3.7	Fecal PQQ concentration	143
4.4	Discussion	144
5	Summary	148
6	References	152